Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Diaceutics ( (GB:DXRX) ) just unveiled an announcement.
Diaceutics reported an estimated 20% rise in 2025 revenues to £38.5 million, a return to profitability and a roughly 75% jump in adjusted EBITDA, underpinned by strong demand for its precision medicine commercialisation platform and greater adoption across 95 therapeutic brands. Annual recurring revenue grew 21% to more than £20.3 million and the order book expanded 48% to at least £36.8 million, reflecting increased multi-year enterprise engagements, including a second PMx commercialisation partnership with a US biotech; with AI-driven efficiency gains and a robust pipeline, the company forecasts 25% revenue growth in 2026, reinforcing its position as a key enabler of the pharma industry’s shift toward precision medicine.
The most recent analyst rating on (GB:DXRX) stock is a Hold with a £142.00 price target. To see the full list of analyst forecasts on Diaceutics stock, see the GB:DXRX Stock Forecast page.
Spark’s Take on GB:DXRX Stock
According to Spark, TipRanks’ AI Analyst, GB:DXRX is a Neutral.
Diaceutics’ strong revenue growth and positive corporate events are overshadowed by challenges in profitability, cash flow, and bearish technical indicators. The stock’s valuation is also concerning due to negative earnings.
To see Spark’s full report on GB:DXRX stock, click here.
More about Diaceutics
Diaceutics PLC is a technology and solutions provider to the pharma and biotech industry, offering end-to-end commercialisation services for precision medicines through data analytics, scientific and advisory services enabled by its DXRX – The Diagnostics Network platform. The company focuses on helping leading global pharmaceutical and biotech companies improve precision testing and therapy adoption, and currently works with 18 of the top 20 global pharma companies across a growing portfolio of therapeutic brands.
Average Trading Volume: 100,311
Technical Sentiment Signal: Buy
Current Market Cap: £119.3M
For an in-depth examination of DXRX stock, go to TipRanks’ Overview page.